To further characterize mechanisms of glucose counterregulation in man, the effects of pharmacologically inducd deficiencies of glucagon, growth hormone, and catecholamines (alone and in combination) on recovery of plasma glucose from insulin-induced hypoglycemia and attendant changes in isotopically ([3-3 H]glucose) determined glucose fluxes were studied in 13 normal subjects. In control studies, recovery of plasma glucose from hypoglycemia was primarily due to a compensatory increase in glucose production; the temporal relationship of glucagon, epinephrine, cortisol, and growth hormone responses with the compensatory increase in glucose appearance was compatible with potential participation of all these hormones in acute glucose counterregulation. Infusion of somatostatin (combined deficiency of glucagon and growth hormone) accentuated insulininduced hypoglycemia (plasma glucose nadir: 36±2 ng/dl during infusion of somatostatin vs. 47±2 mg/dl in control studies, P < 0.01) and impaired restoration of normoglycemia (plasma glucose at min 90: 73±3 mg/dl at end of somatostatin infusion vs. 92±3 mg/dl in control studies, P<0.01). This impaired recovery of plasma glucose was due to blunting of the compensatory increase in glucose appearance since glucose disappearance was not augmented, and was attributable to suppression of glucagon secretion rather than growth hormone secretion since these effects of somatostatin were not observed during simultaneous infusion of somatostatin and glucagon whereas infusion of growth hormone
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INTRODUCTION
Plasma levels of glucagon (1), catecholamines (2) , growth hormone (3), and cortisol (4) increase during hypoglycemia in man. Although each of these has metabolic actions which may potentially reverse hypoglycemia (5) (6) (7) (8) , their individual contribution to the restoration of normoglycemia remains to be established.
Using a sensitive isotope derivative method, Garber et al. (9) noted that early incremenits in plasma catecholamine concentrations during insulin-induced hypoglycemia in human subjects preceded the major compensatory changes in glucose fluxes raising the possibility that adrenergic mechanisms may be important in initiatinig glucose counterregulation. However, factors other than catecholamines must be capable of restoring normoglycemiiia because apparently normal glucose counterregulation has been observed in catecholamine-deficient patients with spinal cord transections (10, 11), epinephrine-deficient adrenalectomized patients (11) (12) (13) (14) , and normal subjects during the infusioIn of a-or ,-adrenergic blocking agents (15) (16) (17) .
It is commonly thought that glucagon, growth hormone, and cortisol also play some role in acute glucose couniterregulation. The administration of somatostatin, an inhibitor of glucagon and growth hormnonie secretion, impairs but does not prevent recovery of plasmla glucose from hypoglycemiia in baboons and normal man (13, 18, 19) . Notably, however, soml-atostatin infusion does prevent recovery of plasma glucose from hypoglycemila in dexamethasone-treated adrenalectomiiized patients (13) . Although chroniic growth hormonie and cortisol excess may cause resistance to the actions of insulin (20, 21) , the importance of acute changes in growth hormone and cortisol secretion in counteracting the acute hypoglycemic action of insulin can be questionied because normal plasma glucose recovery from insulin-induced hypoglycemia has been observed under conditionis in which acute release of these hormones was not possible (12-14, 22, 23) .
These considerations led us to hypothesize that glucagon plays the primary role in acute recovery of plasma glucose from insulin-induced hypoglycemiiia and that adrenergic mechanisms, probably activated by adrenomedullary epinephrine, play a secondary role since they appear to be capable of partially comilpenlsating for glucagon lack (13 Plasma [3-3H] glucose specific activity was determined as follows: duplicate 0.4-ml aliquots of deproteinized plasma were evaporated to dryness at 370C under compressed air to remove tritiated water. The residue was resuspended with 0.5 ml distilled water, and after addition of 10 cm3 Aquasol (New England Nuclear), its radioactivity was counted in a refrigerated liquid scintillation spectrometer. Correction for quenching was made using the method of extemal standard ratios. The average glucose radioactivity of each plasma sample was divided by its glucose concentration to obtain glucose specific activity. Calculated infusion rates of the isotope were verified by measuring the volume of the [3-3H] glucose infusate before and after each experiment.
Plasma growth hormone (24) and glucagon (25) (Unger 30K antibody) were determined by radioimmunoassay. Plasma corticoids were measured by the competitive protein binding method of Murphy (26) . Plasma catecholamines were assayed using a single-isotope derivative method based on the enzymatic conversion of the catecholamines to their respective labeled metanephrines as previously described (27) .
Rates of glucose appearance and disappearance were calculated employing the equations ofWall et al. (28) as modified by DeBodo et al. (29) . This method has been shown to accurately reflect glucose kinetics over a wide range of nonsteady-state plasma glucose levels (30) . All data in the text and figures are expressed as mean±SEM, and their statistical significance was evaluated using Student's two tailed paired t test (31) .
RESULTS
Control studies (Fig. 1 ). All 13 subjects participated in both control and somatostatin studies; their data are shown in Fig. 1 After insulin administration, plasma glucagon increased from a basal value of 99± 12 to 131 ± 13 pg/ml at min 20 (P < 0.001), reached a maximum at min 40, and subsequently decreased to near basal values at min 90. Statistically significant increases in plasma epinephrine (P < 0.001), cortisol (P < 0.05), and growth hormone (P < 0.01) were not observed until min 30. Increases in plasma norepinephrine were not statistically significant until min 50 (P < 0.005). Plasma epinephrine reached maximum levels at min 40 and subsequently decreased toward base-line concentrations; values at min 120 were still significantly (P < 0.01) above base-line levels. Plasma cortisol, growth hormone, and norepinephrine reached maximum levels at min 50-60 and remained significantly (P < 0.05-0.01) above basal values through min 120.
Effect of somatostatin infusion -combined growth hormone and glucagon deficiency (Fig. 1) glucagon slightly below basal levels throughout its infusion; over this interval plasma glucagon levels averaged 95+5 pg/ml compared to basal values of 108±9 pg/ml, P < 0.001. Somatostatin did not suppress plasma growth hormone below basal levels but did impair its increase after insulin-induced hypoglycemia.
In the somatostatin studies, plasma glucose decreased after insulin administration to a nadir of 36+2 mg/dl which was significantly lower than that observed in the control studies (47±2 mg/dl, P < 0.001). All subsequent plasma glucose values during infusion of somatostatin were also significantly less than those observed in the control studies, P < 0.01. The initial increase in glucose disappearance after insulin injection was virtually identical in both somatostatin and control studies; after min 40, however, glucose disappearance was significantly less in the somatostatin studies than that observed in the control studies until discontinuation ofthe somatostatin infusion. The initial decrease in glucose appearance after insulin administration was greater in the somatostatin studies; glucose appearance decreased from a base-line rate to a nadir of 1.02+±0.11 mg/kg per min at min 20 which was significantly lower than that observed in the control studies (1.26±0.11 mg/kg per min, P < 0.05). The subsequent increase in glucose appearance above base-line values was less than that observed in the control studies; the maximum value reached in the somatostatin studies was 2.86±0.18 mg/kg per min at min 50 compared to the maximum of 3.71±0.24 mg/kg per min at min 40 in the control studies (P < 0.001). When the somatostatin infusion was stopped, glucose appearance abruptly increased; this was accompanied by an increase of plasma glucose to base-line values.
Both plasma cortisol and plasma epinephrine increased to greater levels in the somatostatin studies; peak values for plasma cortisol averaged 37+4 compared to 26±3 ,ug/dl in the control studies (P < 0.05). Peak values for plasma epinephrine averaged 582 ± 108 compared to 310+41 pg/ml in control studies (P < 0.01). There was no significant difference in plasma norepinephrine responses in the two studies.
Effect of infusion of somatostatin plus growth hormone -glucagon deficietncy (Fig. 2) . Because infusion of somatostatin in the preceding studies produced combined deficiency of glucagon and growth hormone, in the following study growth hormone was infused along with somatostatin in seven subjects to evaluate the effect of glucagon deficiency in the absence of growth hormone deficiency. During infusion of somatostatin plus growth hormone (10 ,ug/kg per min), plasma growth hormone increased progressively from a basal level of 2.0±0.6 ng/ml to stable levels of 54-58 ng/ml between min 60 and min 90, values 2-to 3-fold greater than those observed in control studies (22-29 ng/ml, P < 0.01) and 10-to 15-fold greater than 3 Effects of glucagon replacement (growth hormone deficiency) on somatostatin (SRIF)-induced alterations in plasma glucose, glucagon, growth hormone, cortisol, epinephrine, norepinephrine levels and the rates of glucose appearance and disappearance after insulin administration.
-growth hormone deficiency (Fig. 3) During infusion of somatostatin plus glucagoni, the profiles of plasma glucose, glucose appearance, and glucose disappearance after insulini administration were virtually identical to those observed in conltrol studies in the same subjects except for a slight overshoot of each at 50-60 min which was not statistically significant. Plasma growth hormone responises remained suppressed. Plasma epinephrine, norepinephrine, and cortisol responses during infusion of somatostatin plus glucagon were not significantly different than those observed during control studies in cointrast to the augmented responses in the circulating levels of these hormones that had been observed during infusion of somatostatin alonie (Fig. 1) .
Effect of infusion of phentolamine and propranolol -a-and f adrenergic blockade (Fig. 4) . To determine the contributioni of catecholamnines to recoverv of plasma glucose from insulin-induced hypoglycemiiia, phentolamine, an a-adrenergic antagonist, and propranolol, a 8-adrenergic antagonist, were infusedl together for 90 min in six subjects after adminiistration of insulin in an attempt to produce com-bined aand 8-adrenergic blockade. In the presence of these agents, neither the plasma glucose nadir nor the rate of recovery of plasma glucose differed significantly from that observed in control studies in the same subjects. Changes in glucose appearance, glucose disappearance, plasma glucagon, and plasma cortisol were also similar to those observed in the control experiments. However, plasma growth hormone and norepinephrine responses were significantly increased. Although plasma epinephrine responses were also greater than those observed in control studies, these differences were not statistically significant. Increases in heart rate accompanying hypoglycemia which had been observed in control studies did not occur during adrenergic blockade.
Effect of infusion of phentola mine, propranolol, and somnatostatin-adrenergic blockade plus glucagont and grotwth hormone deficiency (Fig. 5) . To evaluate the contribution of catecholamines to glucose counterregulation during glucagon (and growth hormone) deficiency, phentolamine and propranolol were infused along with somatostatin after insulin administration in the six subjects studied above. The combined administration of phentolamine, propranolol, and somatostatin further impaired glucose counterregulation after insulin administration compared to that already ob- FIGURE 5 Comparison of plasma glucose, glucagon, growth hormone, cortisol, epinephrine, norepinephrine levels, and the rates of glucose appearance and disappearance after insulin administration during infusion of phentolaminepropranolol-somatostatin (SRIF) x (adrenergic deficiency plus glucagon and growth hormone deficiency) with those observed during infusion of somatostatin alone (glucagon and growth hormone deficiency).
control studies (P < 0.001). The initial suppression of glucose appearance and the initial increase in glucose disappearance after insulin administration were similar during infusion of somatostatin with and without the adrenergic antagonists. Glucose disappearance from mim 50 through mmi 105 was consistently lower during infusion of somatostatin with the adrenergic antagonists than that observed during infusion of somatostatin alone.
During the 90-min infusion of somatostatin, propranolol, and phentolamine, plasma growth hormone and cortisol levels were not significantly different than those observed during infusion of soniatostatin alone. After stopping the infusion of somatostatin plus phentolamine and propranolol, plasma levels of both hormones increased to values significantly (P < 0.01) Hormonal Mfechaniisms of Glucose Counterregulation in Mangreater than those observed during studies in which somatostatin alone had been infused. Plasma glucagon responses were suppressed comparably during infusion of somatostatin with and without the adrenergic antagonists; only at min 30 were plasma glucagon levels significantly different from those observed during infusion of somatostatin alone (82± +10 vs. 110±+-7 pg/mll, respectively P < 0.05). Plasma epinephrine and norepinephrine responses were six-to eightfold greater during infusion of somatostatin plus phentolamine and propranolol than during infusion of somatostatin alone.
DISCUSSION
In the present studies administration of insulin (0.04 U/kg, i.v.) lowered plasma glucose levels as a consequence of both inhibition of glucose appearance and stimulation of glucose disappearance, thus confirming similar observations in dogs (28, 29, (34) (35) (36) and man (9, 36, 37) . As in these previous studies, glucose disappearance returned toward, but not below, base-line values whereas glucose appearance increased from its initially suppressed levels to nearly twice base-line values during recovery of plasmiia glucose from hypoglycemia. Thus, restoration of normoglycemia after insulin-induced hypoglycemia is primarily due to a compensatory increase in glucose production. Therefore, an analysis of the regulatory factors involved in glucose counterregulation should focus primarily on those factors which might rapidly stimulate hepatic glucose production. Both glucagoni (6) and the catecholamines (5) can rapidly augment hepatic glucose production by stimulating glycogenolysis and gluconeogenesis. Although growth hormone and cortisol may increase glucose production by inducing hepatic insulin resistance to insulin (38) , by altering substrate availability (21, 39, 40) or by promoting enzyme induction (8, 21, 40) , neither hormone increases glucose production acutely (40) ; in fact, both hormones have been reported to decrease glucose production within the time frame of the present experiments (41, 42) .
The hormonal secretory patterns and their relationships with the changes in rates of glucose appearanice and disappearance in the present study are in substantial agreement with those reported by Garber et al. (9) , the major difference being the demonstration of a significant increment in plasma glucagon before the onset of glucose counterregulation in the present study.
The reason for this discrepancy is not clear but the present findings indicate that the temporal sequence of glucagon, epinephrine, cortisol, and growth hormone responses in relation to the compensatory increase in glucose appearance is compatible with a role for all these hormones in glucose counterregulation. Thus these temporal relationships by themselves do not permit precise definition of the individual contribution of any of these hormones. Administration of somatostatin prevented both glucagon and growth hormone responses to insulin-induced hypoglycemia; plasma glucose decreased to a lower nadir than had been observed in control studies and recovery of plasm-a glucose to normoglycemia was attenuated. This impaired glucose counterregulation was due solely to a blunting of the comiipensatory increase in glucose appearance since glucose disappearance was not augmented. These effects of somatostatin on impairment ofglucose counterregulation were attributable to suppression of glucagon rather than growth hormone responses. Infusion of somatostatin along with growth hormone, which elevated circulating growth hormone levels two-to threefold above those observed in control studies, did not reverse the effects of somatostatin whereas infusion of somatostatini along with glucagon completely reversed the effects of somatostatin-both those on plasma glucose recovery from hypoglycemia and, in particular, on glucose appearance. These results suggest that intact glucagon secretion is necessary for the normal compensatory increase in hepatic glucose production which is responsible for complete restoration of normoglycemia after insulin administration.
This conclusion, however, must be coinsidered in view ofthe fact that circulating glucagon levels achieved in the above studies were two-to threefold greater than those observed in control studies. Based on previous reports (32, 33) indicating a portal-peripheral venous gradient for glucagon of -2.2 during augmented glucagon secretion, the glucagon infusion rate of 3 ng/kg per min was chosen in an attempt to approximate the portal venous glucagon levels observed in the control studies, i.e. levels 2.2 times the peripheral venous glucagon levels observed in the control studies. At each of the six sampling points during the glucagon infusion the ratio of these values did not differ significantly from the desired theoretical value of 2.2. However, when all individual data (42 samples) were analyzed together, their mean (2.7) significantly exceeded the desired value, indicating a possible overinfusion of glucagon by as much as 22%. This, coupled with the fact that glucagon infusions were begun at 0 time, may well explain the elevation of glucose concentrations to levels somewhat above the control values during somatostatin combined with glucagon. Nonetheless, the fundamental observation that glucagon administration prevented the somatostatin-induced impairment of glucose recovery from hypoglycemia, whereas growth hormone administration did not, remains.
Although the compensatory increase in glucose production and restoration of normoglycemia after insulin-induced hypoglycemia were impaired in the 68 presence of somatostatin, it is notable that a compensatory increase in glucose appearance and partial recovery of plasma glucose from hypoglycemia did occur. This could have been due to epinephrine since augmented responses of this hormone occurred during the somatostatin studies and since plasma glucose recovery from insulin-induced hypoglycemia was totally prevented in similar studies performed in adrenalectomized patients (13) . Furthermore, the fact that glucose disappearance was significantly decreased during the later portion ofthe somatostatin infusion compared to values in the control studies is also consistent with an epinephrine effect since epinephrine is known to decrease glucose clearance in man (43) .
To evaluate the contribution of catecholamines in acute glucose counterregulation, both phentolamine, an a-adrenergic antagonist, and propranolol, a /3-adrenergic antagonist, were infused after insulin administration at doses conventionally used to achieve adrenergic receptor blockade. Although circulating epinephrine and norepinephrine levels observed during hypoglycemia were increased by this maneuver, infusion of these agents had no effects on glucose counterregulation. Similar results have been obtained with measurements of circulating glucose levels (15, 16) and glucose fluxes (17) in previous studies during selective a-or p-adrenergic blockade. These observations and those indicating that normal glucose recovery from insulin-induced hypoglycemia can occur in spinal cord transected (10, 11) and in adrenalectomized (11) (12) (13) (14) Finally, it should be pointed out that in these latter studies some glucose counterregulation was evident despite apparent adrenergic blockade and inhibition of both glucagon and growth hormone secretion; plasma glucose and glucose appearance increased respectively from nadirs of 36+2 mg/dl and 0.88+0.08 mg/kg per min to peak values of 52+5 mg/dl and 2.02 +0.27 mg/kg per min. Several explanations are possible. Firstly, circulating epinephrine and norepinephrine levels were markedly increased to values in excess of 2.7 and 1.7 ng/ml, respectively. The conventional doses of phentolamine and propranolol used in these studies have been shown to block the metabolic effects of epinephrine infused at a rate of 6 jig/min (44) (45) (46) . This infusion rate has been reported to produce circulating epinephrine levels of <1 ng/ml (47) which is below those seen in the present studies. Thus, since the adrenergic blocking agents used in the present study are competitive antagonists, it is possible that incomplete adrenergic blockade occurred due to the extreme elevation of both norepinephrine and epinephrine plasma levels. A second possible explanation is an intrinsic effect of hypoglycemia on the liver (48); increased glucose release from rat livers perfused in vitro has been observed after lowering glucose perfusate levels (48, 49) . Finally, activation of sympathetic or parasympathetic innervation of the liver (50) (51) (52) (53) and sympathetic inhibition of insulin secretion (54-56) could also have been involved. This latter effect would have permitted lower concentrations of counterregulatory factors to be more effective stimulants of glucose production and could have contributed along with hypoglycemia (43, 57) , to the decrease observed in glucose disappearance. These sympathetic effects would have been possible if the doses of the adrenergic antagonists employed in the present study had been insufficient to completely block the effects of norepinephrine released from sympathetic nerve terminals within the liver.
In conclusion, the present studies indicate that in man: (a) restoration of normoglycemia after insulininduced hypoglycemia is primarily due to a compensatory increase in glucose production; (b) intact glucagon, but not growth hormone, secretion is necessary for normal glucose counterregulation; and (c) adrenergic mechanisms do not normally play an essential role in this process but become critical to recovery from hypoglycemia when glucagon secretion is impaired.
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